In the published article, there was an error in Figure 7C as published. The red label and black label were reversed. The corrected Figure 7C and its caption is as follows: “(C) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor, 2 μM) or alisertib (AURKA inhibitor, 10 μM) for 0, 12, 24, 32, 48, and 60 h, and cell viability was determined by Calcein-AM/PI staining assays.”
FIGURE 7
Gambogenic acid (EZH2 inhibitor) and alisertib (AURKA inhibitor) inhibit HCC cell proliferation, migration, and invasion. (A) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor) or alisertib (AURKA inhibitor) at different concentrations (0–100 μM) for 48 h, and cell viability was determined by Calcein–AM/PI staining assays. (B) Hep3B and Huh7 cells were treated with DMSO (solvents of gambogenic acid and alisertib) at different concentrations (0–100 μM) for 48 h, and cell viability was determined by Calcein–AM/PI staining assays. (C) Hep3B and Huh7 cells were treated with gambogenic acid (EZH2 inhibitor, 2 μM) or alisertib (AURKA inhibitor, 10 μM) for 0, 12, 24, 32, 48, and 60 h, and cell viability was determined by Calcein–AM/PI staining assays. (D) Colony formation assays were conducted to analyze Hep3B and Huh7 cell proliferation with gambogenic acid (2 μM) or alisertib (10 μM) treatment. (E, F) Wound healing assays (E) and Transwell assays (F) were performed to detect the cell migratory abilities of Hep3B and Huh7 cells treated with gambogenic acid (2 μM) or alisertib (10 μM). (G) Transwell assays were performed to detect the cell invasion abilities of Hep3B and Huh7 cells treated with gambogenic acid (2 μM) or alisertib (10 μM). Data are expressed as the means ± s.d. Differences were considered statistically significant if p < 0.05. ns, no significance, *p < 0.05, **p < 0.01, ***p < 0.001. (H, I) Expression of AURKA (H) and EZH2 (I) in TCGA–LIHC based on TP3 mutation status.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
AURKA, EZH2, tyrosine kinase inhibitors, TKI, protein kinases, cell cycle, single-cell RNA sequencing, hepatocellular carcinoma
Citation
Yao F, Zhan Y, Li C, Lu Y, Chen J, Deng J, Wu Z, Li Q, Song Y, Chen B, Chen J, Tian K, Pu Z, Ni Y and Mou L (2023) Corrigendum: Single-cell RNA sequencing reveals the role of phosphorylation-related genes in hepatocellular carcinoma stem cells. Front. Cell Dev. Biol. 11:1045260. doi: 10.3389/fcell.2023.1045260
Received
15 September 2022
Accepted
11 October 2023
Published
23 October 2023
Volume
11 - 2023
Edited and reviewed by
Lei Dong, Beijing Institute of Technology, China
Updates
Copyright
© 2023 Yao, Zhan, Li, Lu, Chen, Deng, Wu, Li, Song, Chen, Chen, Tian, Pu, Ni and Mou.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zuhui Pu, pupeter190@163.com; Yong Ni, szniyong@sina.com; Lisha Mou, lishamou@gmail.com
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.